Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JULIO A GONZALEZ-PAOLI

Allopathic & Osteopathic Physicians Internal Medicine Rheumatology

NPI
1336331271
CMS profile
150934
Location
TAMPA, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$242,091.11

490 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

By paying entity

PY2023 · entire year · sorted by reported total

Page 5 of 10; records 201–250 of 490 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JULIO A GONZALEZ-PAOLI

NPI 1336331271 · CMS profile ID 150934

Allopathic & Osteopathic Physicians / Internal Medicine / Rheumatology

TAMPA, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 5 of 10; records 201–250 of 490 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1336331271?year=2023&recipient=provider&page=5#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JULIO A GONZALEZ-PAOLI, NPI 1336331271, CMS profile ID 150934. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 5 of 10; records 201–250 of 490 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1336331271?year=2023&recipient=provider&page=5#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). JULIO A GONZALEZ-PAOLI, NPI 1336331271, CMS profile ID 150934. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 5 of 10; records 201–250 of 490 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1336331271?year=2023&recipient=provider&page=5#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
JULIO A GONZALEZ-PAOLI, NPI 1336331271, CMS profile ID 150934, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 5 of 10; records 201–250 of 490 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1336331271?year=2023&recipient=provider&page=5#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

490 matching records · $242,091.11 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 490 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 201–250 of 490.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Organon LLC $27.8608/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1046940799 CMS
Mallinckrodt Hospital Products Inc. $19.5608/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1042834955 CMS
ANI Pharmaceuticals, Inc. $33.8808/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1034156925 CMS
Amgen Inc. $12.2708/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1019982195 CMS
GlaxoSmithKline, LLC. $21.5308/10/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1003126417 CMS
ABBVIE INC. $6.9408/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997366691 CMS
ABBVIE INC. $17.3908/08/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997366689 CMS
Aurinia Pharma U.S., Inc. $23.8608/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1057734105 CMS
GlaxoSmithKline, LLC. $684.4008/04/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1003126327 CMS
GlaxoSmithKline, LLC. $967.6808/04/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1003127929 CMS
GlaxoSmithKline, LLC. $12.0008/03/2023 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1061461084 CMS
GlaxoSmithKline, LLC. $57.0008/03/2023 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1061463492 CMS
UCB, Inc. $23.2308/03/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1021559003 CMS
GlaxoSmithKline, LLC. $4,550.0008/02/2023 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1003128047 CMS
Janssen Biotech, Inc. $275.0008/02/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988111483 CMS
Janssen Biotech, Inc. $131.0008/02/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988111577 CMS
Novartis Pharmaceuticals Corporation $24.9408/02/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991991249 CMS
Novartis Pharmaceuticals Corporation $1.6108/02/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 991991253 CMS
UCB, Inc. $19.9408/02/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1021558949 CMS
ABBVIE INC. $25.3307/31/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997366687 CMS
UCB, Inc. $108.0807/31/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1021559085 CMS
UCB, Inc. $3,700.0007/31/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1021583127 CMS
UCB, Inc. $1,150.0007/31/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1021588987 CMS
UCB, Inc. $3,700.0007/31/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1021589021 CMS
ABBVIE INC. $15.4507/29/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997366685 CMS
Janssen Biotech, Inc. $3,850.0007/29/2023 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988111557 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $20.6607/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996946315 CMS
Janssen Biotech, Inc. $95.2507/27/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988111567 CMS
ABBVIE INC. $17.5207/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 997366683 CMS
Amgen Inc. $73.6007/26/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1020611755 CMS
Lilly USA, LLC $22.8107/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031721905 CMS
AstraZeneca Pharmaceuticals LP $15.4207/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015761165 CMS
Horizon Therapeutics plc $29.3307/23/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 987008095 CMS
GlaxoSmithKline, LLC. $39.8007/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1002794611 CMS
Janssen Biotech, Inc. $517.7007/22/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988111507 CMS
Janssen Biotech, Inc. $90.0007/22/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988111517 CMS
Janssen Biotech, Inc. $15.0007/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988111527 CMS
Janssen Biotech, Inc. $35.0007/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988111537 CMS
Janssen Biotech, Inc. $31.1207/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 988111547 CMS
UCB, Inc. $16.3507/22/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1021558915 CMS
AstraZeneca Pharmaceuticals LP $20.3907/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014831139 CMS
GENZYME CORPORATION $74.9007/21/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1050180343 CMS
Amgen Inc. $46.7507/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1020611699 CMS
UCB, Inc. $19.9207/19/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1021558943 CMS
Amgen Inc. $155.2407/18/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1020611703 CMS
Amgen Inc. $87.0007/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1020611711 CMS
Amgen Inc. $131.6107/18/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1020611713 CMS
Amgen Inc. $12.5907/18/2023 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1020611715 CMS
AstraZeneca Pharmaceuticals LP $22.1007/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014464709 CMS
UCB, Inc. $9.5907/18/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1021526135 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $160,872.54 371
PY2020 $94,660.04 191
PY2021 $105,287.73 344
PY2022 $157,477.92 373
PY2023 $242,091.11 490
PY2024 $303,913.29 531
PY2025 $297,358.89 458

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $382,744.36 26
PY2024 Recipient $84,788.26 2
PY2024 Principal investigator $39,898.24 15
PY2023 Principal investigator $35,933.70 15
PY2022 Principal investigator $92,162.79 40
PY2021 Principal investigator $113,949.27 54
PY2020 Principal investigator $176,428.89 63
PY2019 Principal investigator $298,045.25 57

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

26 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $159.96 12/04/2025 Covered Recipient Teaching Hospital
ST. JOSEPHS HOSPITAL
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) No dispute reported 06/30/2026 1202421428
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $28,859.75 12/03/2025 Covered Recipient Teaching Hospital
Orlando Health
A Phase 2, Multicenter, Open-Label Study Of CC-97540 (BMS-986353), CD19-Targeted NEXT CAR T Cells, in Participants with Active SLE (Including Lupus Nephritis) with Inadequate Response to Glucocorticoids and at Least 2 Immunosuppressants (Breakfree-SLE) No dispute reported 06/30/2026 1236000408
Principal investigator 1 ABBVIE INC. $2,313.12 11/04/2025 Covered Recipient Teaching Hospital
ST. JOSEPHS HOSPITAL
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) No dispute reported 06/30/2026 1202421426
Principal investigator 1 ABBVIE INC. $4,453.87 10/09/2025 Covered Recipient Teaching Hospital
ST. JOSEPHS HOSPITAL
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) No dispute reported 06/30/2026 1202421421
Principal investigator 1 Novartis Pharmaceuticals Corporation $38,253.00 10/01/2025 Non-covered Recipient Entity
FLORIDA MEDICAL CLINIC
A Phase 2, Randomized, Open-label, Controlled Study to Evaluate the Efficacy and Safety of Rapcabtagene Autoleucel Versus Comparator in Participants With Severe Refractory Idiopathic Inflammatory Myopathies (IIM) No dispute reported 06/30/2026 1190304659
Principal investigator 1 Novartis Pharmaceuticals Corporation $25,951.52 10/01/2025 Non-covered Recipient Entity
FLORIDA MEDICAL CLINIC PA
A Phase II, multi-part, three-year, randomized, open-label, assessor-blinded, active-controlled, multicenter study to evaluate the efficacy and safety of rapcabtagene autoleucel versus rituximab treatment in participants with severe refractory diffuse cut No dispute reported 06/30/2026 1190313551
Principal investigator 1 Novartis Pharmaceuticals Corporation $2,016.32 09/18/2025 Non-covered Recipient Entity
FLORIDA MEDICAL CLINIC
A Phase 2, Randomized, Open-label, Controlled Study to Evaluate the Efficacy and Safety of Rapcabtagene Autoleucel Versus Comparator in Participants With Severe Refractory Idiopathic Inflammatory Myopathies (IIM) No dispute reported 06/30/2026 1190304657
Principal investigator 1 ABBVIE INC. $2,048.37 09/03/2025 Covered Recipient Teaching Hospital
ST. JOSEPHS HOSPITAL
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) No dispute reported 06/30/2026 1202421417
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $1,388.91 08/26/2025 Non-covered Recipient Entity
Florida Medical Clinic
A Phase 2, Multicenter, Open-Label Study Of CC-97540 (BMS-986353), CD19-Targeted NEXT CAR T Cells, in Participants with Active SLE (Including Lupus Nephritis) with Inadequate Response to Glucocorticoids and at Least 2 Immunosuppressants (Breakfree-SLE) No dispute reported 06/30/2026 1235997313
Principal investigator 1 Eli Lilly and Company $1,915.00 08/19/2025 Non-covered Recipient Entity
INTERNATIONAL CENTER FOR RESEARCH
A PHASE 4, PROSPECTIVE, OPEN-LABEL, SINGLE-ARM STUDY TO ASSESS THE EFFECTIVENESS OF TIRZEPATIDE AFTER INITIATION OF IXEKIZUMAB IN ADULT PARTICIPANTS WITH ACTIVE PSORIATIC ARTHRITIS AND OVERWEIGHT OR OBESITY IN CLINICAL PRACTICE No dispute reported 06/30/2026 1187883866
Principal investigator 1 ABBVIE INC. $1,790.37 08/05/2025 Covered Recipient Teaching Hospital
ST. JOSEPHS HOSPITAL
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) No dispute reported 06/30/2026 1202421413
Principal investigator 1 ABBVIE INC. $1,362.70 07/02/2025 Covered Recipient Teaching Hospital
ST. JOSEPHS HOSPITAL
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) No dispute reported 06/30/2026 1202421408
Principal investigator 1 UCB SA $47,558.00 06/27/2025 Non-covered Recipient Entity
INTERNATIONAL CENTER FOR RESEARCH
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF DAPIROLIZUMAB PEGOL IN STUDY PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS No dispute reported 06/30/2026 1246659637
Principal investigator 1 ABBVIE INC. $2,653.12 06/03/2025 Covered Recipient Teaching Hospital
ST. JOSEPHS HOSPITAL
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) No dispute reported 06/30/2026 1202421404
Principal investigator 1 Novartis Pharmaceuticals Corporation $3,269.60 06/01/2025 Non-covered Recipient Entity
FLORIDA MEDICAL CLINIC PA
A Phase II, multi-part, three-year, randomized, open-label, assessor-blinded, active-controlled, multicenter study to evaluate the efficacy and safety of rapcabtagene autoleucel versus rituximab treatment in participants with severe refractory diffuse cut No dispute reported 06/30/2026 1190313549
Principal investigator 1 ABBVIE INC. $1,660.97 05/06/2025 Covered Recipient Teaching Hospital
ST. JOSEPHS HOSPITAL
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) No dispute reported 06/30/2026 1202421399
Principal investigator 1 ABBVIE INC. $239.68 05/01/2025 Covered Recipient Teaching Hospital
ST. JOSEPHS HOSPITAL
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Participants With Psoriatic Arthritis Who Have an Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD) No dispute reported 06/30/2026 1202421395
Principal investigator 1 ABBVIE INC. $3,689.52 04/03/2025 Covered Recipient Teaching Hospital
ST. JOSEPHS HOSPITAL
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) No dispute reported 06/30/2026 1202421392
Principal investigator 1 ABBVIE INC. $2,869.63 03/06/2025 Covered Recipient Teaching Hospital
ST. JOSEPHS HOSPITAL
M15-998 - A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) No dispute reported 06/30/2026 1202421388
Principal investigator 1 Eli Lilly and Company $4,837.67 02/25/2025 Non-covered Recipient Entity
INTERNATIONAL CENTER FOR RESEARCH
EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH ACTIVE PSORIATIC ARTHRITIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSA) No dispute reported 06/30/2026 1187883574
Principal investigator 1 UCB SA $12,979.06 02/07/2025 Non-covered Recipient Entity
INTERNATIONAL CENTER FOR RESEARCH
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF DAPIROLIZUMAB PEGOL IN STUDY PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS No dispute reported 06/30/2026 1246657634
Principal investigator 1 ABBVIE INC. $2,573.78 02/05/2025 Covered Recipient Teaching Hospital
ST. JOSEPHS HOSPITAL
M15-998 - A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) No dispute reported 06/30/2026 1202421383
Principal investigator 1 UCB SA $4,275.00 01/20/2025 Non-covered Recipient Entity
INTERNATIONAL CENTER FOR RESEARCH
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF DAPIROLIZUMAB PEGOL IN STUDY PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS No dispute reported 06/30/2026 1246658332
Principal investigator 1 Eli Lilly and Company $183,349.00 01/07/2025 Non-covered Recipient Entity
INTERNATIONAL CENTER FOR RESEARCH
EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH ACTIVE PSORIATIC ARTHRITIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSA) No dispute reported 06/30/2026 1187883228
Principal investigator 1 ABBVIE INC. $1,485.00 01/06/2025 Covered Recipient Teaching Hospital
ST. JOSEPHS HOSPITAL
M14-465 - A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate No dispute reported 06/30/2026 1202421380
Principal investigator 1 ABBVIE INC. $791.44 01/02/2025 Covered Recipient Teaching Hospital
ST. JOSEPHS HOSPITAL
M15-998 - A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) No dispute reported 06/30/2026 1202421376